All In Biotech

Drug Trial Radar · NCT06570031

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

ONO-4578-06: Phase I , Open-label, Non-blind, First-line Endocrine Therapy With ONO-4578 and Standard Treatment Letrozole and CDK4/6 Inhibitors (Palbociclib or Abemaciclib) in Patients With Metastatic or Recurrent Postmenopausal Hormone Receptor-positive HER2-negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Nov 9, 2021

Primary completion

Apr 30, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, non-controlled, phase I study to investigate the tolerability and safety of ONO-4578 used in combination with standard-of-care letrozole and a CDK4/6 inhibitor (palbociclib or Abemaciclib) as first-line endocrine therapy in postmenopausal patients with metastatic or recurrent hormone receptor-positive, HER2-negative breast cancer.

Conditions

  • Hormone Receptor-positive Breast Cancer
  • HER2-negative Breast Cancer
  • Metastatic Breast Cancer
  • Recurrent Breast Cancer

Interventions

  • ONO-4578Drug

    Specified dose on specified days

  • letrozoleDrug

    Specified dose on specified days

  • PalbociclibDrug

    Specified dose on specified days

  • abemaciclibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Through study completion, an average of 4 year
  2. Serious adverse eventsTime frame: Through study completion, an average of 4 year
  3. Dose-limiting toxicity (Tolerability Confirmation part only)Time frame: 28 days
  4. Laboratory abnormality profile of Drugs as measured by incidence and severity of clinical laboratory abnormalitiesTime frame: Through study completion, an average of 4 year
  5. Body temperatureTime frame: Through study completion, an average of 4 year
  6. Pulse rateTime frame: Through study completion, an average of 4 year
  7. Systolic/diastolic blood pressureTime frame: Through study completion, an average of 4 year
  8. Saturation of Percutaneous Oxygen (SpO2)Time frame: Through study completion, an average of 4 year
  9. WeightTime frame: Through study completion, an average of 4 year
  10. Eastern Cooperative Oncology Group Performance StatusTime frame: Through study completion, an average of 4 year
  11. Chest X-rayTime frame: Through study completion, an average of 4 year
  12. CT scanTime frame: Through study completion, an average of 4 year
  13. 12-lead electrocardiography (Heart rate)Time frame: Through study completion, an average of 4 year
  14. 12-lead electrocardiography (PR interval)Time frame: Through study completion, an average of 4 year
  15. 12-lead electrocardiography (RR interval)Time frame: Through study completion, an average of 4 year
  16. 12-lead electrocardiography (QRS width)Time frame: Through study completion, an average of 4 year
  17. 12-lead electrocardiography (QT interval)Time frame: Through study completion, an average of 4 year

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • Chiba Cancer Center

    Chiba, Chiba, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan

  • St. Marianna University Hospital

    Kawasaki-shi, Kanagawa, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • Saitama Cancer Center

    Shinden, Saitama, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • The Cancer Institute Hospital Of JFCR

    Koto-ku, Tokyo, Japan

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.